Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Cerilliant
Queensland Health
Healthtrust
Deloitte
Medtronic
AstraZeneca
Accenture
Federal Trade Commission
US Army

Generated: December 11, 2017

DrugPatentWatch Database Preview

US Patents With Foreign Priority to United Kingdom Patent: 9614755

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms CorpTYKERBlapatinib ditosylateTABLET;ORAL022059-001Mar 13, 2007RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
Novartis Pharms CorpTYKERBlapatinib ditosylateTABLET;ORAL022059-001Mar 13, 2007RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
Novartis Pharms CorpTYKERBlapatinib ditosylateTABLET;ORAL022059-001Mar 13, 2007RXYesYes► Subscribe► Subscribe► SubscribeYYTREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
Novartis Pharms CorpTYKERBlapatinib ditosylateTABLET;ORAL022059-001Mar 13, 2007RXYesYes► Subscribe► Subscribe► SubscribeYYTREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist